医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

IHMA Opens Microbiology Reference Laboratory in Shanghai, China to Further Support Global Anti-Infective Product Discovery and Development

2021年09月22日 PM11:30
このエントリーをはてなブックマークに追加


 

SCHAUMBURG, Ill.

IHMA has opened a microbiology reference laboratory in Shanghai, China in February of 2021. This facility will join IHMA locations in the USA, Switzerland and India to allow the company to provide more robust global support for anti-infective product discovery and development. The China facility will provide microbiology testing to support profiling of new antimicrobial products, antimicrobial resistance surveillance, molecular characterization of resistant organisms, and serve as a central laboratory for clinical trials conducted in China.

“We have been working for almost 30 years to maximize our in vitro support for clients who are developing anti-infective products globally. Our facility in China will greatly enhance that effort and support clients wishing to conduct studies in this important market,” said Jack L. Johnson, President/CEO of IHMA.

About IHMA:

As the leading global microbiology service provider to the biopharmaceutical industry, IHMA utilizes its extensive laboratory and industry expertise to support efficient and effective anti-infective product development. IHMA is a premier provider of reference laboratory services to support anti-infective product discovery and development as well as the development of diagnostic devices that detect bacterial resistance to antimicrobial agents and new technologies as they emerge.

For more information, please visit IHMA’s website (www.ihma.com).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005605/en/

CONTACT

Darcie Carpenter PhD CIC

Director Global Business Development

+1.530.577.5296

dcarpenter@ihma.com

Ian Morrissey MBA PhD FRSM

Chief Scientific & Development Officer

+44.01279.724929

imorrissey@ihma.com

同じカテゴリーの記事 

  • FPT Software Renews HITRUST r2 Certification, Upholding The Highest Standards Of Security And Compliance
  • Rapid Medical™使用全球首台机器人血栓切除设备成功完成缺血性中风手术
  • ラピッド・メディカル™が世界初のロボット血栓除去装置で虚血性脳卒中手技を成功裏に完了
  • AriBio获得国家药品监督管理局对一项治疗早期阿尔茨海默病的3期临床试验POLARIS-AD的IND批准
  • AriBio Receives IND Approval from China’s NMPA for POLARIS-AD, a Phase 3 Trial for the Treatment of Early Alzheimer’s Disease